Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2023-03-20 00:00:00 ET · period of report 2023-03-16 · accession 0001209191-23-020043 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-03-20 | 2023-03-16 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $300.59 | -2,746 | 49.5K | -5% | -$825.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-16 | S | D | 264 | $301.07 | 49,268 | D | — | — | (F2) Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F4) Open market sales reported on this line occurred at a weighted average price of $301.07 (range $301.00 to $301.14). |
| 2 | Common | Common Stock | 2023-03-16 | S | D | 2,482 | $300.54 | 49,532 | D | — | — | (F2) Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F3) Open market sales reported on this line occurred at a weighted average price of $300.54 (range $300.00 to $300.94). |